Unknown PHASE2 INTERVENTIONAL 1-arm NCT05596890

Patient-reported Outcomes in Preoperative Immunochemotherapy/Radiotherapy-treated Esophageal Cancer Patients (PICCRT)

Patient-reported Outcome-based Surveillance System Evaluating Safety and Efficacy of Preoperative Immunochemotherapy +/- Chemoradiation in Patients With Esophageal Squamous Cell Carcinoma - A Prospective, Explorative, Phase II Study

Sponsor: Guangdong Provincial People's Hospital

Conditions Esophageal Squamous Cell Carcinoma Immunotherapy Patient-reported Outcomes

Interventions Carboplatin Cisplatin Esophagectomy Paclitaxel-albumin Tislelizumab VMAT or IMRT

Updated 5 times since 2022 Last updated: Nov 24, 2022 Started: Nov 30, 2022 Primary completion: Sep 30, 2025 Completion: Sep 30, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Esophageal Squamous Cell Carcinoma and Immunotherapy and is currently ongoing. Guangdong Provincial People's Hospital leads this study, which shows 5 recorded versions since 2022 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Nov 2025 — Present [monthly]

Unknown PHASE2

Status: Recruiting → Unknown
Sep 2024 — Nov 2025 [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2
Dec 2022 — Jul 2024 [monthly]

Recruiting PHASE2
Nov 2022 — Dec 2022 [monthly]

Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Guangdong Provincial People's Hospital

Data source: Guangdong Provincial People's Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Guangzhou, China